Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 6/20 | 0.48 |
| ▸ | NPY4R | P50391 | 9/20 | 0.42 |
| ▸ | NPY1R | P25929 | 6/20 | 0.42 |
| ▸ | NPY2R | P49146 | 5/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.42 |
| ▸ | EED | O75530 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20951659 | 1.00 | KISS1R (0.48) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20951352 | 0.97 | KISS1R (0.45) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20951350 | 0.97 | KISS1R (0.45) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20950992 | 0.95 | KISS1R (0.48) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20950991 | 0.95 | KISS1R (0.48) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20951952 | 0.92 | KISS1R (0.46) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20951954 | 0.92 | KISS1R (0.46) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20952281 | 0.86 | NPY4R (0.47) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20952279 | 0.86 | NPY4R (0.47) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL20951339 | 0.85 | KLKB1 (0.43) | KISS1REEDPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | TGFB1, TGFB2, SMAD3 | KISS1R 2444/4885NPY4R 3053/4885NPY1R 3152/4885 |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | TGFB1, TGFB2, SMAD3 | KISS1R 2444/4885NPY4R 3053/4885NPY1R 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.